{"id":406746,"date":"2025-08-29T00:30:00","date_gmt":"2025-08-28T22:30:00","guid":{"rendered":"https:\/\/medizinonline.com\/?p=406746"},"modified":"2025-08-28T22:18:50","modified_gmt":"2025-08-28T20:18:50","slug":"medicaments-biologiques-peptide-oral-et-nanobody-trivalent-resultats-et-tendances-actuels","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/fr\/medicaments-biologiques-peptide-oral-et-nanobody-trivalent-resultats-et-tendances-actuels\/","title":{"rendered":"M\u00e9dicaments biologiques, peptide oral et nanobody trivalent &#8211; r\u00e9sultats et tendances actuels"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>L&#8217;icotrokinra et le sonelokimab ont tous deux donn\u00e9 lieu \u00e0 des r\u00e9sultats de haut niveau qui attestent d&#8217;un grand potentiel th\u00e9rapeutique pour ces candidats m\u00e9dicaments innovants. Mais il existe \u00e9galement de nouvelles preuves extr\u00eamement int\u00e9ressantes issues d&#8217;\u00e9tudes cliniques et du monde r\u00e9el concernant les anticorps monoclonaux actuellement autoris\u00e9s appartenant aux groupes des inhibiteurs de l&#8217;interleukine (IL)-23 et de l&#8217;IL-17. Dans l&#8217;esprit de la m\u00e9decine personnalis\u00e9e, il s&#8217;agit de plus en plus de choisir une option th\u00e9rapeutique adapt\u00e9e \u00e0 chaque situation parmi la multitude de possibilit\u00e9s de traitement.    <\/strong><\/p>\n\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/fr\/mon-compte\/paquets\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/fr\/se-connecter\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Ffr%2Fmedicaments-biologiques-peptide-oral-et-nanobody-trivalent-resultats-et-tendances-actuels%2F\">Connectez-vous ici<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>L&#8217;icotrokinra et le sonelokimab ont tous deux donn\u00e9 lieu \u00e0 des r\u00e9sultats de haut niveau qui attestent d&#8217;un grand potentiel th\u00e9rapeutique pour ces candidats m\u00e9dicaments innovants. Mais il existe \u00e9galement&#8230;&hellip;... <\/p>\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/fr\/mon-compte\/paquets\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/fr\/se-connecter\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Ffr%2Fmedicaments-biologiques-peptide-oral-et-nanobody-trivalent-resultats-et-tendances-actuels%2F\">Connectez-vous ici<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":406747,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Psoriasis et PsA  ","footnotes":"[{\"content\":\"OMS-5 : il s'agit de l'indice de bien-\\u00eatre de l'OMS, o\\u00f9 0 signifie l'absence de bien-\\u00eatre et 100 un bien-\\u00eatre maximal (le seuil pour un changement cliniquement significatif est de 10 points).\",\"id\":\"0eb10af1-4631-44c6-b46a-a26d220fe05b\"},{\"content\":\"WPAI : le questionnaire sur la productivit\\u00e9 au travail et l'alt\\u00e9ration de l'activit\\u00e9 comprend les domaines suivants : absences au travail, travail dans un \\u00e9tat alt\\u00e9r\\u00e9 (pr\\u00e9sent\\u00e9isme), perte de productivit\\u00e9 au travail et alt\\u00e9ration de l'activit\\u00e9.\",\"id\":\"e80dbffb-1eb1-437f-9f1c-48d573f78cda\"},{\"content\":\"Tous les patients ont re\\u00e7u le bimekizumab-bkzx toutes les quatre semaines (q4w) jusqu'\\u00e0 la semaine 16, puis ont re\\u00e7u soit le q4w, soit le q8w, en fonction de leur r\\u00e9ponse au traitement. Si vous recevez q4w jusqu'\\u00e0 la semaine 16, q8w est ensuite le sch\\u00e9ma posologique approuv\\u00e9 (q4w\\\/q8w). Les r\\u00e9sultats ont port\\u00e9 sur des patients recevant \\u00e0 la fois q4w\\\/q8w et q4w\\\/q4w.  \",\"id\":\"03b46733-3caf-4a5d-bf29-6aec9d08b811\"}]","_members_access_role":[],"_members_access_error":""},"category":[11549,11349,11362,11527,11535,11505],"tags":[13407,27094,18140,84526,12408,84525,84524,15735,14035,26407,12604,84527,67793,27009],"powerkit_post_featured":[],"class_list":["post-406746","post","type-post","status-publish","format-standard","has-post-thumbnail","category-rx-fr","category-allergologie-et-immunologie-clinique","category-dermatologie-et-venerologie","category-etudes","category-rapports-de-congres","category-rhumatologie","tag-arthrite-psoriasique","tag-bimekizumab-fr","tag-guselkumab-fr","tag-icotrokinra-fr","tag-medicaments-biologiques","tag-nanobody-trivalent","tag-peptide-oral","tag-psa-fr","tag-psoriasis-fr-2","tag-risankizumab-fr","tag-secukinumab-fr","tag-sonelokimab-fr","tag-tildrakizumab-fr","tag-zdft-fr","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-07-22 15:54:57","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"fr_FR","wpml_translations":{"it_IT":{"locale":"it_IT","id":406743,"slug":"biologici-peptidi-orali-e-nano-corpi-trivalenti-risultati-e-tendenze-attuali","post_title":"Biologici, peptidi orali e nano-corpi trivalenti - risultati e tendenze attuali","href":"https:\/\/medizinonline.com\/it\/biologici-peptidi-orali-e-nano-corpi-trivalenti-risultati-e-tendenze-attuali\/"},"pt_PT":{"locale":"pt_PT","id":406749,"slug":"biologicos-peptidos-orais-e-nanocorpos-trivalentes-resultados-e-tendencias-actuais","post_title":"Biol\u00f3gicos, p\u00e9ptidos orais e nanocorpos trivalentes - resultados e tend\u00eancias actuais","href":"https:\/\/medizinonline.com\/pt-pt\/biologicos-peptidos-orais-e-nanocorpos-trivalentes-resultados-e-tendencias-actuais\/"},"es_ES":{"locale":"es_ES","id":406740,"slug":"biologicos-peptidos-orales-y-nanoanticuerpos-trivalentes-resultados-y-tendencias-actuales","post_title":"Biol\u00f3gicos, p\u00e9ptidos orales y nanoanticuerpos trivalentes: resultados y tendencias actuales","href":"https:\/\/medizinonline.com\/es\/biologicos-peptidos-orales-y-nanoanticuerpos-trivalentes-resultados-y-tendencias-actuales\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/406746","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/comments?post=406746"}],"version-history":[{"count":1,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/406746\/revisions"}],"predecessor-version":[{"id":406748,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/406746\/revisions\/406748"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media\/406747"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media?parent=406746"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/category?post=406746"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/tags?post=406746"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/powerkit_post_featured?post=406746"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}